Business Context and Reporting Period
Company: Pluristem Therapeutics Inc. (PSTI)
Filing Type: Form 8-K (Current Report)
Date of Report: May 5, 2020
Principal Office: Haifa, Israel
Exchange: The Nasdaq Capital Market
The filing reports the entry into a Material Definitive Agreement regarding a registered public offering of common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Securities Purchase Agreement with two institutional investors.
- Shares Issued: 1,587,302 shares of Common Stock.
- Purchase Price: $9.45 per share.
- Net Proceeds: Approximately $15,000,000.
- Use of Proceeds: Working capital, funding Phase II study of PLX cell therapy for COVID-19 complications, other clinical trials, capital equipment, and general corporate purposes.
- Expected Closing: On or before May 7, 2020.
Note: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the company's operations.
Material Changes
The filing discloses a material change in the company's capital structure through the issuance of new equity. There is no prior comparable period data provided in this specific 8-K filing to assess operational changes.
Outlook, Risks, and Management Commentary
Management Commentary: The company intends to utilize the proceeds specifically to advance its clinical pipeline, with a highlighted focus on the treatment of complications arising from COVID-19.
Risks and Contingencies: The closing of the offering is subject to customary closing conditions. The filing includes standard legal disclaimers stating that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the final closing date of the offering (expected by May 7, 2020).
- Confirm the exact net proceeds received after deducting transaction costs.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.
- Monitor subsequent filings for updates on the Phase II COVID-19 clinical trial progress.